ROSETTA GENOMICS (NASDAQ:ROSG)
2.10
0.03 (1.41%)
| ROSETTA GENOMICS (NASDAQ:ROSG) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $2.13 | 52 Week High | $3.80 | ||
| Open | $2.10 | 52 Week Low | $1.08 | ||
| Day High | $2.12 | P/E | N/A | ||
| Day Low | $2.07 | EPS | $0.00 | ||
| Volume | 14,300 | ||||
| More ROSG Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| BGP | 1 | GNW | 1 |
| ENCO | 1 | CAEI | 1 |
| GNW | 1 | EXXI | 1 |
| CAEI | 1 | KONA | 1 |
| HITK | 1 | CBK | 1 |
| KONA | 1 | LRN | 1 |
Entities who have mentioned ROSG
- Bankruptcy | View Related Stories »
- Deutsche Bank | View Related Stories »
- Unusual 11 Mid-Day Movers | View Related Stories »
- Treasury Capital Purchase Program | View Related Stories »
- Barack Obama | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- 13G | View Related Stories »
- Collins Stewart | View Related Stories »
- Maxim Group | View Related Stories »
StreetInsider.com Major News for ROSG
View All ReportsStreetInsider.com Reports on ROSG
- Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower
- Cantor Fitzgerald Downgrades Rosetta Genomics (ROSG) to Hold; Higher Execution Risk
- Rosetta Genomics (ROSG) and Super Religare Laboratories Sign Exclusive Distribution Agreement
- Rosetta Genomics (ROSG) Reports a Q1 Loss
- Unusual 11 Mid-Day Movers 4/13: CAEI, FEED, GCI, BGP Higher; GNW, SPW, WFR, GM Lower
View All Press ReleasesCompany Press Releases on ROSG
- Rosetta Genomics Strengthens MicroRNA Intellectual Property Position with Receipt of Additional Patent
- Rosetta Genomics Names Kenneth A. Berlin President and Chief Executive Officer
- Rosetta Genomics to Present at Scientific Conference; Provides Update on Colon Cancer Diagnostic Program
- Rosetta Genomics Names Genetic Technologies Limited Exclusive Distributor for Rosetta's microRNA-based Assays in Australia, New Zealand and Singapore
- Prometheus Launches ProOnc Dx Cancer Diagnostics
StreetInsider Reports on ROSG by Category
View All BlogsBlogs on ROSG
- Rigel Pharmaceuticals: Biotech Crisis or Opportunity?
- Rosetta Genomics Ltd. Q2 2008 Earnings Call Transcript
- Rosetta Genomics: Mining Genes From Junk (Part II)
- Analyst initiations 7-24-07: CELL, DFS, MA and X
- Analyst initiations 6-28-07: AZN, DUK, JMP and SPR
View All FilingsSEC Filings on ROSG
- Form SC 13G Rosetta Genomics Ltd. Filed by: Far West Capital Management
- Form 6-K Rosetta Genomics Ltd. For: Nov 16
- Form 6-K Rosetta Genomics Ltd. For: Nov 03
Comments on recent ROSG articles
Comments on ROSG
No comments are currently available.
on Feb 20, 2008
at 03:42 PM INSM A $3.00 dollar stock trading below a $1.00.
Article: Analyst Call of the Year: Collins Stewart on Encysive (ENCY)